TFM
JBIO

TFC Financial Management’s Jade Biosciences JBIO Stock Holding History

TFC Financial Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67 Hold
3
– – ﹤0.01% 968
2026
Q1 		$43 Hold
3
– – ﹤0.01% 958
2025
Q4 		$47 Buy
+3
New +$35 ﹤0.01% 932

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TFC Financial Management's JBIO Position: Q2 2026 in Review

TFC Financial Management held its Jade Biosciences (JBIO) position steady in Q2 2026 at 3 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #968.

TFC Financial Management first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • TFC Financial Management held 3 shares of Jade Biosciences worth $67 as of Q2 2026.
  • TFC Financial Management left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of TFC Financial Management's portfolio in Q2 2026, its #968 holding.
  • TFC Financial Management first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.